Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Healthtrust
Dow
Chinese Patent Office
Boehringer Ingelheim
Fuji
Daiichi Sankyo
US Army
Merck

Generated: April 23, 2018

DrugPatentWatch Database Preview

VERSAPEN Drug Profile

« Back to Dashboard

When do Versapen patents expire, and when can generic versions of Versapen launch?

Versapen is a drug marketed by Bristol and is included in three NDAs.

The generic ingredient in VERSAPEN is hetacillin potassium. There are six drug master file entries for this compound. Additional details are available on the hetacillin potassium profile page.
Drug patent expirations by year for VERSAPEN
Synonyms for VERSAPEN
(2S,%R,6R)-6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure
(2S,5R,6R)-6-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
3511-16-8
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2S-(2alpha,5alpha,6beta(S*)))-
6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
6-(2,2-Dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure
6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid
6beta-[(4R)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
7-(2,2-dimethyl-5-oxo-4-phenyl-imidazolidin-1-yl)-3,3-dimethyl-6-oxo-2-thia-5-azabicyclo[3.2.0]heptane-4-carboxylic acid
AC1L9EKH
AKOS027381814
BL-P 804
BL-P-804
BRL 804
BRL-804
C-23897
C11729
CC-29245
CHEBI:5683
CHEMBL1201116
CS-4870
D01074
DB00739
DR002253
DXVUYOAEDJXBPY-NFFDBFGFSA-N
EINECS 222-512-5
etacillin
Etacillina
Etacillina [DCIT]
FT-0771485
HE337458
Hetacilina
Hetacilina [INN-Spanish]
hetacillin
Hetacillin (USAN/INN)
Hetacillin [USAN:USP:INN:BAN]
Hetacilline
Hetacilline [INN-French]
Hetacillinum
Hetacillinum [INN-Latin]
HY-16251A
N,N'-Isopropylidene-A-amino-benzyl penicillin
N.N'-Isopropylidene-A-amino-benzyl penicillin
penplenum
Phenazacillin
SCHEMBL34131
TN4JSC48CV
UNII-TN4JSC48CV
Versapen (TN)
Versapen-k
ZINC4102186

US Patents and Regulatory Information for VERSAPEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol VERSAPEN hetacillin FOR SUSPENSION;ORAL 061398-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol VERSAPEN hetacillin FOR SUSPENSION;ORAL 061398-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol VERSAPEN hetacillin FOR SUSPENSION;ORAL 050060-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol VERSAPEN hetacillin FOR SUSPENSION;ORAL 050060-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
AstraZeneca
Boehringer Ingelheim
Fish and Richardson
Cantor Fitzgerald
Harvard Business School
Julphar
Johnson and Johnson
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.